The private equity investor Nordic Capital invests EUR 450m in LEO Pharma. Nordic Capital becomes an active minority owner and will partner with LEO Pharma’s majority owner the LEO Foundation.
LEO Pharma is a global leader in medical dermatology. The investment will strengthen the company’s market position and help accelerate innovation and growth through upcoming product launches and a continued focus on LEO Pharma’s market-leading established product portfolio.
LEO Pharma is headquartered in Denmark with a global team of 6,000 employees, serving 93 million patients in more than 130 countries.
Since its formation in 1989, Nordic Capital has invested in 29 healthcare companies across Europe and North America. Today, Nordic Capital has 14 portfolio companies in the healthcare sector.
The transaction is subject to approval by the relevant authorities and is expected to be completed in the first half of 2021.
Accura advised Nordic Capital in connection with the investment.